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Abstract 
This article aims to analyse the spending trends of global pharmaceutical companies 
for Marketing, Sales and for Research and Development. Evaluating the spending 
structure of pharmaceutical companies, one has to realise that they are spending more and 
more on Marketing and Sales than for Research and Development. We are analysing the 
regulation differences among countries with a special attention to Hungary and 
Kazakhstan. In Hungary the pharmaceutical market is well developed. The spending 
structure is changing slowly, the local company is still focusing more on Research and 
Development than on promotion and advertising. The pharmaceutical businesses of 
Kazakhstan are still in infancy but from the very beginning the marketing expenditure 
overwhelms the Research and Development expenses. 
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1. Introduction 
The article analyses the expenditure on Research and Development by the industry sectors 
for the period 2005-2015. Also we consider the spending of the top 10 major companies in the 
world focused on Research and Development for ten years. In this paper we analyse the 
Marketing and sales expenditures of the global pharmaceutical companies for the period for 
2000-2015 years. The accurate statistics are often missing so we have to estimate the 
expenditure on Marketing and Sales as well as on Research and Development.  
We tried to focus on those companies in Hungary and in Kazakhstan where the appropriate 
data were available. In our detailed study we looked at a more detailed analysis only of the 
Hungarian and Kazakhstan pharmaceutical industries. Of course, we have also looked at some 
of the most important players in the world's pharmaceutical industry as well. 
Also we cannot generalise the results, which are based on two companies, one 
representing Hungary, this is Richter Gedeon, which is still an independent Hungarian 
company and still has original drugs, where the patent is their own, and the other on is a 
Kazakhstan pharmaceutical company Chempharm, which focuses on the production of 
generic drugs. Also this is bias from the stand point of the comparison but we cannot find 
a pharmaceutical company in Kazakhstan which has its original drugs for sale. Beside the 
market statistics, we are considering the regulation differences among the countries with 
special attention to Hungary and Kazakhstan.  
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Currently pharmaceutical companies are spending proportionally less on Research and 
Development year by year. The development of new drugs is a costly and time consuming 
process. The research activity of creating new drugs requires millions of dollars and the 
licensing process may take some decades. The shortest time frame is at least 10-15 years.  
«Big Pharma says this occurs because of the astronomical costs of developing a new 
drug. The truth is that United States law allows drug companies to set the prices for drugs 
and protects them from free-market competition. Other countries set a limit on what 
companies can charge based on the benefit of the drug. The true cost of developing a drug 
is shrouded in mystery with many unverifiable figures reported by Big Pharma. 
Advertising instead of research: For each dollar spent on «Basic research» Big Pharma 
spends $19 on promotions and advertising in medical journals, internet, television, radio 
and in other instruments to attract the attention of consumers» (Llamas M, 2016).  
«There are some challenges and «threats» within the industry. The first question is the 
sustainability of growth, but not less important the ever-increasing cost to bring new drugs 
to the market and the profitability loss because of the increasing marketing and Research 
and Development costs. The prices of the drugs vary in Europe and in different regions of 
the World. The uptake of new drugs to the market is slowing down and the patent 
expiration issues are harder than used to be in the past» (Rod M., 2007). 
2. Literature review 
Literature mainly deals with the question of the research intensity of the 
pharmaceutical industry. Researchers generally agree that the pharmaceutical industry is 
one of the most knowledge demanding industries. Austin made a good comparison with 
other industries to show the research intensity of the pharmaceutical sector: «The 
pharmaceutical industry is one of the most industries dependent on intensive research in 
the United States. According to the Congressional Budget Office «The pharmaceutical 
companies invest as much as five times more in Research and Development relative to 
their sales than the average United States manufacturing company. In the United States 
common rate of Research and Development for a pharmaceutical company is about 17% 
of it is sales that is far higher than other industries» (Austin D, 2006). 
There is also a consensus among scholars that the profitability of companies is largely 
determined by research and marketing costs. Evans and Drummond and others summarize 
it well in their papers:  
«In pharmaceutical industry Research and Development plays a key role on developing 
of new drugs, which has a tremendous effect on companies’ profitability according to 
patent. On the other hand, drug and health service constitute a large volume of advertising 
in the world. It is reason is that there is asymmetric information between the customer and 
seller» (Evans R, 1995). «Two factors affecting companies’ profitability are costs related: 
one is Research and Development and the other is marketing cost» (Drummond M, 1992). 
«Although the pharmaceutical industry emphasizes how much money it devotes to 
discovering new drugs, little of that money actually goes into basic research. Data from 
companies, the United States National Science Foundation, and government reports 
indicate that companies have been spending only 1.3% of revenues on basic research to 
discover new molecules, net of taxpayer subsidies» (Lexchin, 2005). 
The authors generally agree that marketing costs are growing rapidly in the industry: 
«Marketing budgets in the pharmaceutical industry are huge by comparison to most other 
industries, but they are often predominantly spent on the marketing channel, delivering the 
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product to the customer. These characteristics seem to indicate that the simple linear 
model of innovation still captures the overall approach to innovation in the pharmaceutical 
industry» (Trott P., 2002). 
In contrast the authors disagree on the causes of the rapid increase in marketing costs. 
Most authors (Stremersch) argue that this is the «speciality» of this industry and stresses 
the difficulties of delivering information on medicines to consumers. Stremersch speaks 
about «specialized marketing knowledge»: «The pharmaceutical industry spends a notably 
large percentage of its revenues on marketing. United States pharmaceutical companies 
spend on average more on marketing, compared to their average Research and 
Development expenditure. The pharmaceutical industry requires specialized marketing 
knowledge. The market faces unique challenges in facets such as new product 
development, life cycle management and marketing management» (Stremersch S, 2008). 
Some other authors like Manchanda P. focus more on the «unic challenges» of the industry: 
«Pharmaceutical companies are characterized by a large number of new drugs launches. For 
instance around 41 completely new drug molecules were launched each year on average (IMS 
Health). However, the industry faces many unique challenges in developing and 
commercializing innovations. Most notably the industry faces high risk (on average one success 
from 10.000 original compounds), high cost (typically greater than $800 million for each 
successful drug), a long development cycle (12 years on average) with a limited product life 
(effective patent protection is only 8–10 years)» (Manchanda P, 2005). 
The others focus more on the personnel costs related to the doctor-visitor system: «In 
the pharmaceutical industry there has been a traditional triad relationship among doctors, 
patients and pharmacists. As medical professionals are the ones who directly treat patients 
for their ailments, their recommendations are highly regarded. In addition, medical doctors 
play an important role in decision-making process in planning pharmaceuticals that are 
carried in the formulary of their individual/group private practices and/or hospitals. 
Consequently pharmaceutical companies in general invest a handsome amount of 
resources in personal selling and other related marketing activities for promoting 
pharmaceuticals to the medical practitioners» (Liu S, 2004). 
The majority of the authors (Smith, Lakdawalla, Rosenthal, Rubin) focus on the positive 
effect of marketing. Smith speaks about the «promotion of hope and promise». «Marketing has 
two main objectives: first, it should maintain present customers of it are products and services 
and second, it should attract new customers toward the products and services. Scientific and 
experimental advances of marketing in recent years resulted in it is action scope expansion and 
increase the success rate of this science and therefore have converted it» beyond advertisement 
and promotion of hope and promise» (Smith M, 2014).  
The others speak about the general aim of advertisement: «to persuade consumers that 
the advertised product is better». 
«Today the pharmaceutical world realizes that it should spend a significant amount 
from its investment for drug marketing in order to increase drug prescription level as well 
as enhance the customer satisfaction level. For instance 10 leading pharmaceutical 
companies in the world annually spend 34% of their sales on updating drug prescription 
by physicians and internal marketing» (Lakdawalla D, 2013).  
«The literatures of the effect of advertising on prescribing practices have shown that 
such advertising increases class wide sales, helps to avert under use of medicines to treat 
chronic conditions and leads to some overuse of prescription drugs» (Rosenthal M, 2003). 
«However supporters of pharmaceutical promotions claim that marketing expenditures 
give innovative pharmaceutical manufacturers a fair chance to recover high Research and 
20 
Development expenditures. Moreover marketing may serve as a communication channel 
to educate physicians and expose consumers to information that may improve their health 
outcomes and medical options» (Rubin P, 2003). 
3. The Expenditure on Research and Development by Industry  
for 2005-2015 years 
Understanding the role of Research and Development in the pharmaceutical industry 
we have to compare it with other industries. We see in Figure 1 that $120 billion was 
spent in 2005 on Computing and Electronics, which increased to $166 billion in 2015. 
Then the Pharmaceutical industry spent $144 billion on Research and Development in 
2015, which was $90 billion in 2005 that shows an increase. Auto industry spent in 2015 
less than $109 billion and in 2005 it was $70 billion. In 2015 Industrials spent $75 billion, 
so an increase can be seen, which was in 2005 less than $40 billion. Also on Software and 
Internet $76 billion was spent in 2015 and in 2005 it was $30 billion. In the last ten years 
there are changes but the pharmaceutical industry is still the second most research 
concentrated industry in the world after Computing and Electronics (See Figure 1 and 
Table 1). 
 
Figure 1.: The Expenditure on Research and Development by Industry  
for 2005-2015 years in billion $ 
 
Source: Strategy & pwc 2015 Global Innovation 1000, 2005-2015 
 
Figure 1 and Table 1 shows the expenditure on Research and Development in the 
Industry for 2005-2015 years. 
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Table 1.: The Expenditure on Research and Development by Industry  
for 2005-2015 years in billion $ 
Sectors 2005 in billion $ 2015 in billion $ 
Computing and Electronics 120 166 
Pharmaceutical   90 145 
Automative   70 109 
Industrials   40   75 
Software and Internet   30   76 
Source: Strategy & pwc 2015 Global Innovation 1000, 2005-2015 
 
As we see here in Table 2 among the most Research and Development oriented 
companies from the top 10 five companies are pharmaceutical. In 2005 pharmaceutical 
company Sanofi was the first with $9.3 billion Research and Development expenditure. In 
2015 automotive company Volkswagen took the lead with a significant increase in 
expenditure of $15.3 billion on Research and Development compared to 2005. Then the 
computing and electronic company Samsung comes with expenditure of $14.1 billion on 
Research and Development, which is much more than in 2005. Software and Internet 
Company Microsoft  spent $11.4 billion on Research and Development (See Table 2).  
 
Table 2.: Top 10 companies oriented on Research and Development  
for 2005-2015 years in billion $ 
№ Companies Countries Sectors 
Research and 
Development 
2005 
in billion $ 
Research and 
Development 
2015 
in billion $ 
  1. 
 
Germany Automotive 4.7 15.3 
  2. 
 
South Korea Computing and electronics 4.3 14.1 
  3. USA Software& Internet 7.8 11.4 
  4. 
 
Switzerland Pharmaceutical 4.1 10.8 
  5. 
 
Switzerland Pharmaceutical 4.2 9.1 
  6. 
 
USA Pharmaceutical 7.7 8.4 
  7. 
 
Germany Automotive 7.0 7.6 
  8. 
 
USA Automotive 6.5 7.4 
  9. 
 
France Pharmaceutical 9.3 6.4 
10. 
 
UK Pharmaceutical 5.2 5.7 
Source: Strategy & pwc, The Global Innovation 1000: Top 20 Research  
and Development Spenders 2005-2015 
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Table 2 shows the Top 10 companies oriented on Research and Development for 2005-
2015 years. 
Pharmaceutical company Roche spent $10.8 billion on Research and Development, 
which significantly increased in comparison with 2005. The next pharmaceutical company 
Novartis spent $9.1 billion on Research and Development. The pharmaceutical company 
Pfizer is not concedes and spent $8.4 billion. Automotive companies Daimler and General 
Motors spent almost the same $7.6 billion and $7.4 billion on Research and Development. 
Pharmaceutical company Sanofi spent $6.4 billion on Research and Development less 
than in 2005. The pharmaceutical company GSK almost did not change its expenditure on 
Research and Development of $5.7 billion compared to 2005. But these are only slight 
changes and the pharmaceutical industries still keep their position among the most 
innovative companies (See Table 2).  
3.1. The shift in expenditure of global pharmaceutical companies 
The role of Marketing, Sales and Research and Development expenditure is the most 
influencing one in the pharmaceutical industry. The other expenditures are stable, so we 
decided to study how much pharmaceutical companies spend for Marketing, sales and for 
Research and Development. In such circumstances, testing the relationship between 
Research and Development expenditure and advertising costs with the profitability of the 
pharmaceutical market can be interesting (Acosta A, 2014). 
Figure 2 and Table 3 consider the largest share of expenditure on Marketing, sales and 
on Research and Development of pharmaceutical companies. The pharmaceutical 
company GSK in 2000 spent $16.0 billion on marketing and sales and $3.8 billion was 
spent on Research and Development. Also in 2015 GSK spent $9.2 billion for Marketing 
and sales, lower than in 2000, but higher than for the Research and Development $5.7 
billion. The pharmaceutical company Pfizer in 2015 spent $14.8 billion on Marketing and 
sales, rather more than for Research and Development $8.4 billion. In 2000 on Marketing 
and Sales $11.4 billion was spent and on Research and Development as little as $4.4 
billion (See Figure 2 and Table 3). 
Figure 2 and Table 3 show the expenditure of the Top-5 global pharmaceutical 
companies on Marketing, Sales and Research and development in 2000-2015 years 
The next pharmaceutical company Novartis in 2015 spent $11.7 billion on Marketing 
and Sales compared to Research and Development of $9.1 billion. In 2000 it spent $10.9 
billion on Marketing and Sales more than for Research and Development spends $4.6 
billion. The only one pharmaceutical company Roche in 2015 spent $10.8 billion on 
Research and Development, almost the same on Marketing and Sales, $9.1 billion. In 2000 
Roche spent more on Marketing and Sales, $9.0 billion, but the same as in 2015 and on 
Research and Development $4.1 billion, which is comparably less. The pharmaceutical 
company Sanofi in 2015 spent $9.8 billion on Marketing and sales, more than on Research 
and Development, which was $6.4 billion. In 2000 Sanofi's expenditure was significantly 
reduced on Marketing and Sales $2.3 billion and on Research and Development $1.1 
billion (Figure 2 and Table 3). 
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Figure 2.: The Expenditure of Top 5 global pharmaceutical companies for Marketing,  
Sales and for Research and Development in 2000-2015 years in billion $ 
 
Source: Pfizer, Annual report, 2000; Pfizer, Annual report, 2015; Novartis, Annual report , 2000; 
Novartis, Annual report, 2015; Sanof, Annual report, 2000; Sanofi, Annual report, 2015;  
Roche, Annual report , 2000; Roche, Annual report, 2015; GlaxoSmithKline, Annual report, 2000; 
GlaxoSmithKline, Annual report, 2015 
 
Table 3.: The Expenditure of the Top 5 global pharmaceutical companies on Marketing,  
Sales and on Research and Development in 2000-2015 years in billion $ 
№ Company 
Marketing and 
Sales 2000 
in billion $ 
Research and 
Development 
2000 
in billion $ 
Marketing and 
Sales 2015 
in billion $ 
Research and 
Development 
2015 
in billion $ 
1. Pfizer 11.4 4.4 14.8   8.4 
2. Novartis 10.9 4.6 11.7   9.1 
3. Sanofi   2.3 1.1   9.8   6.4 
4. Roche   9.0 4.1   9.1 10.8 
5. GSK 16.0 3.8   9.2   5.7 
Source: Pfizer, Annual report, 2000; Pfizer, Annual report, 2015; Novartis, Annual report, 2000; 
Novartis, Annual report, 2015; Sanof, Annual report, 2000; Sanofi, Annual report, 2015;  
Roche, Annual report , 2000; Roche, Annual report, 2015; GlaxoSmithKline, Annual report, 2000; 
GlaxoSmithKline, Annual report, 2015 
3.2. The Expenditure on Marketing, Sales and on Research and Development  
of pharmaceutical products in Hungary 
In the Hungarian pharmaceutical market 77% of medicines were sold in pharmacies 
and only 23% in hospitals in 2015. In 2015 the Hungarian pharmaceutical industry 
invested $310 344 million in Research and Development. This industry employs more 
than 15 000 employees. In Diagram 3 we see that the most identical Hungarian 
pharmaceutical company Richter Gedeon spent 98 310 million HUF on Marketing and 
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Sales in 2015 and on Research and Development 34 822 million HUF. In 2000 Richter 
Gedeon 10 672 million HUF was spent on Marketing and Sales and 5 611 million HUF on 
Research and Development (See Diagram 3) (Richter, G, Annual Report, 2000-2015). 
 
Diagram 3.: Changes in Marketing and Research and Development costs at Richter Gedeon 
pharmaceutical company between 2000 and 2015 in million HUF 
 
Source: Richter, G, Annual Report, 2000-2015 
 
Diagram 3 and Table 4 show the changes in the Marketing and Research and 
Development costs at Richter Gedeon pharmaceutical company between 2000 and 2015. 
As you can see in Diagram 3 and in table 4, in 2015 Richter Gedeon spent on the 
marketing nine times, and on Research and Development six times more than in year 
2000, which means the expenditure on marketing grew much faster than the expenditure 
on research and development which is in harmony with the world trends (See Diagram 3 
and Table 4). 
 
Table 4.: Changes in Marketing and Research and Development costs at Richter Gedeon 
pharmaceutical company between 2000 and 2015 in million HUF 
Richter Gedeon  
company 
2000 in million 
HUF 
2015 in million 
HUF 
Growth 
2000-2015 in% 
Marketing and Sales 10 672 98 310 927 
Research and Development   5 611 34 822 620 
Marketing/Research and  
   Development Cost ratio 
1.9 2.8 - 
Source: Richter, G, Annual Report, 2000-2015 
 
Among the independent Hungarian pharmaceutical companies Richter Gedeon is a 
leader in investment in research, their share in the total turnover is almost 10%, which in 
absolute terms puts the company in the 1st place concerning the level of expenditure on 
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Research and development in the country and in Central and Eastern Europe as well 
(Report Hungary Pharmaceuticals&Healthcare). 
The pharmaceutical companies spend €4.0 million on advertisements in medical 
journals in Hungary. The total amount spent by pharmaceutical companies on product 
advertisements in the 115 Hungarian printed medical journals came to almost 1.2 billion 
HUF (€4 million), Comfit, a media monitoring company, which specializes in medical 
journals, revealed it to Central Europe Pharma News. The same companies spend 478.7 
million HUF (€1.6 million) on advertising the companies themselves (not their products). 
Richter Gedeon led the field in terms of advertising expenditure, with a figure of 90.4 
million HUF (€303.000). In the second place there were Egis and Woerwag Pharma 
(Central Europe Pharma News Issue , 2013).  
3.3. The Expenditure on generic drugs and on Marketing  
of pharmaceutical products in Kazakhstan 
The pharmaceutical market of Kazakhstan was estimated at $1.7 billion in 2015, the 
market is divided into retail pharmacy sales and government procurement. In Diagram 4 
we can see the structure of the pharmaceutical market in Kazakhstan from 2000 to 2015 as 
imports remain between 78% and 92%. Out of these domestic production of 
pharmaceutical products occupies only 22%. The main parts of the product portfolios of 
domestic manufacturers are low-profit generic drugs (share in the total market volume is 
90%) and the market of the original drugs is 10%, which allows pharmaceutical 
manufacturers to allocate their profits on Research and Development of new original 
drugs (See Diagram 4 and Table 5). 
 
Diagram 4.: Structure of the pharmaceutical market in Kazakhstan  
for 2000-2015 years in % 
 
Source: Consulting Agency “Vi-ORTIS”; Single Distributor, SK-Pharmacy 
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Diagram 4 and Table 5 show the structure of the pharmaceutical market in Kazakhstan 
for 2000-2015 years. 
In 2015 retail pharmaceutical market occupied 33% of the total Kazakhstan market, 
hospital segment 67%. The retail segment is widely represented by well-known drugs. The 
rating of the most growing and large market includes vitamins, remedies for cold diseases, for 
the treatment of the gastrointestinal tract, as well as antibiotics and painkillers. 
The hospital sector of procurement of medicines has been more oriented on purchase from 
domestic manufacturers of pharmaceutical products since 2010, thus the state supports 
domestic manufacturers of pharmaceutical products for the development of the pharmaceutical 
industry in Kazakhstan. For the period from 2010 to 2015 the share of pharmaceutical 
products purchased through the Single Distributor increased on average, 3 times from 35.8 to 
107.5 billion KZ tenge (See Diagram 4 and Table 5) (Single Distributor, SK-Pharmacy). 
 
Table 5.: Structure of the pharmaceutical market in Kazakhstan for 2000-2015 years in % 
Kazakhstan 2000 in% 2015 in% 
Production 8 22 
Import 92 78 
Original 5 10 
Generic 95 90 
Hospital segment 30 44 
Retail market 70 56 
Source: Consulting Agency “Vi-ORTIS”; Single Distributor, SK-Pharmacy 
 
The biggest Kazakhstan pharmaceutical company Chempharm specialized in generic 
drugs spends much less on marketing than on production of generic drugs. Graph 5 shows 
how the pharmaceutical company Chempharm spends a very small share of its income of 
15.1 million KZ tenge on marketing. The production of generic drugs in 2015 produced 
733.3 million KZ tenge, which means that even a large company produces generic drugs. 
However, in 2000 it produced more than 843 million tenge (See Diagram 5 and Table 6). 
 
Diagram 5.: The Expenditure on generic drugs and on marketing of the pharmaceutical 
company Chempharm of Kazakhstan in 2000-2015 years in million KZ tenge 
 
Source: Chempharm, Annual report, 2000-2015 
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Diagram 5 and Table 6 show the g expenditure on generic drugs and on Marketing of 
the pharmaceutical company Chempharm of Kazakhstan in 2000-2015 years. 
 
Table 6.: The expenditure on generic drugs and on marketing of the pharmaceutical  
company Chempharm of Kazakhstan in 2000-2015 years in million KZ tenge 
Chempharm 
company 
2000 in million 
KZ tenge 
2015 in million 
 KZ tenge 
Generic drugs 843 000 000 733 354 000 
Marketing          33 641   15 196 000 
Source: Chempharm, Annual report, 2000-2015 
 
Foreign pharmaceutical companies in Kazakhstan spend about 10-15% of annual 
turnover on marketing programs to introduce doctors their products, including sponsoring 
a conference and publication. In the over-the-counter segment where direct advertising of 
medicines for consumers is allowed, foreign manufacturers also managed to increase their 
market share. Foreign pharmaceuticals increased their market share thanks to advertising, 
despite the fact that domestic medicines were cheaper but they were not properly 
advertised. In Kazakhstan imported branded generics and innovative drugs are very 
popular among physicians and pharmacy staff often recommend patients who they cured. 
3.4. The regulation of advertising and promotion of pharmaceutical  
products in the United States, Europe, Hungary and Kazakhstan 
In Table 7 we consider how each country regulates the advertising of pharmaceutical 
products. In the United States marketing and distribution of pharmaceuticals is heavily 
regulated by the federal Prescription Drug Marketing Act. In general, pharmaceutical 
companies adhere to FDA regulatory guidelines that require all DTC ads and information 
to be accurate in order to provide substantive evidence of any statements that have been 
made, to strike a balance between the risks and benefits of the product being promoted and 
to maintain consistency with the labeling approved by the FDA (U.S. Food and Drug 
Administration, FDA). Europeans still have quite limited exposure to pharmaceutical 
advertisements for prescription drugs. The EU is of particular attraction to pharmaceutical 
companies, however, as it accounts for a full one-third of global drug sales. In Europe, the 
advertising is regulated by the International Federation of the Pharmaceutical Industry 
Manufacturers and Associations (Eagle L., 2002) (See Table 7). 
Here are the details about the regulation of advertising and promotion of 
pharmaceutical products in Hungary and Kazakhstan. In Hungary the sales promotion sent 
to doctors and advertisements in publications shall be regulated by law. Professional/ 
scientific audit and punishment for false and biased promotional materials the National 
Institute of pharmacy and Nutrition (OGYEI) has the liability (Lengyel G., 2007).  
Advertising in Kazakhstan drugs shall be conducted in accordance with the order of the 
Ministry of health of the Republic of Kazakhstan. In Kazakhstan advertising of drugs is 
regulated by the Law of the Republic of Kazakhstan «On Advertising» and National center 
for expertise of drugs (National center for expertise of drugs, Dari.kz) (See Table 7). 
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Table 7.: The regulation of advertising and promotion of pharmaceutical products  
in the United States, Europe, Hungary and Kazakhstan 
Countries Regulation Laws 
United States In the United States marketing and distribution of pharmaceuticals 
is heavily regulated by the federal Prescription Drug Marketing Act. 
In general pharmaceutical companies adhere to FDA regulatory 
guidelines which call for all DTC advertising and information to be 
accurate, to provide substantial evidence for any claims that are 
made, to provide a balance between the risks and benefits of the 
promoted drug, and to maintain consistency with labeling approved 
by the FDA (U.S. Food and Drug Administration, FDA). 
U.S. Food and Drug 
Administration 
 
Europe Europeans still have quite limited exposure to pharmaceutical 
advertisements for prescription drugs. The EU is of particular 
attraction to pharmaceutical companies, however, as it accounts for 
a full one-third of global drug sales (Eagle L., 2002). 
International 
Federation of 
Pharmaceutical 
Manufacturers and 
Associations 
(IFPMA). 
Hungary In Hungary the sales promotion sent to doctors and  
advertisements in publications shall be regulated by law. 
Professional/scientific audit and punishment for false and biased 
promotional materials, the National Institute of pharmacy and 
Nutrition (OGYEI) has the liability. Other non-scientific part of the 
promotion is governed by the advertising law and the Code of 
ethics of the pharmaceutical industry of all pharmaceutical 
companies in Hungary (Lengyel G, 2007). 
National Institute of 
pharmacy and 
Nutrition (OGYEI). 
Kazakhstan Advertising in Kazakhstan drugs shall be conducted in accordance 
with the order of the Ministry of health of the Republic of 
Kazakhstan. In Kazakhstan advertising of drugs is regulated by the 
Law of the Republic of Kazakhstan «On Advertising» and also 
National center for expertise of drugs (National center for expertise 
of drugs, Dari.kz).  
Law of the Republic 
of Kazakhstan «On 
Advertising» and also 
National center for 
expertise of drugs.  
 
Table 7 shows the regulation of advertising and promotion of pharmaceutical products 
in the United States, Europe, Hungary and Kazakhstan. 
4. Conclusion 
The article analyses the expenditure on Research and Development by the industry 
sectors for the period 2005-2015. We have considered the costs of ten leading companies 
in the world focusing on Research and Development for 10 years. In this article we have 
studied the expenditure on Research and Development and on Marketing, sales of global 
pharmaceutical companies for the period 2000-2015. The top 5 global pharmaceutical 
companies spend more on marketing and sales than on R&D, and since 2000 the gap has 
been permanently increasing. The R&D expenditure used to be above 40 % and in 2015 it 
was less than 30 % in three from five cases.  
We have estimated the expenditure of a Hungarian company, this is Richter Gedeon, 
which is still an independent Hungarian company and still has original medicines where 
the patent belongs to them and also the Kazakhstan company Chempharm, which focuses 
on the production of generic drugs. It is also a bias in terms of comparison, but we could 
not find a pharmaceutical company in Kazakhstan that has its own original drugs for sale. 
In addition to market statistics, we have considered the differences in regulation between 
countries with special attention to Hungary and Kazakhstan. 
This trend exisst in Hungary and in Kazakhstan as well. The Hungarian companies 
promote their products in journals and through radio and television heavily. 
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We compared the regulation of advertising and promotion of pharmaceutical products 
in the United States, Europe, and in Hungary and Kazakhstan. 
We recommend the Governments and the International institutions to implement means 
which drive the pharmaceutical companies back to research. The governments should set 
limits for the advertisement in this field. They have to promote the open an the 
crowdsourcing innovations to make this kind of public good affordable for the poor as 
well. 
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